Becker's Healthcare April 1, 2025
A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 among U.S. adults without diabetes.
The research, published April 1 in the Annals of Internal Medicine, showed the number of non-diabetic adults using these drugs — which are...